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Background: To investigate on expressions and clinical significances of CD133 protein and vasculogenic mimicry
(VM) in primary non-small cell lung cancer (NSCLC).
Methods: The specimens of NSCLC from 305 Chinese patients with follow-up were analyzed for CD133 protein
expression and VM by immunohistochemical and histochemical staining.
Results: In NSCLC, positive rates of 48.9% and 35.7% were obtained for CD133 and VM, respectively. The VM and
expression of CD133 were significantly higher in carcinoma than in normal. There were a positive relationship
between the VM and expression of CD133 and the tumor grade, lymph node metastasis and clinical stage (all
P<0.05). The overall mean survival time of the patients with CD133 and VM positive expression was lower than that
of patients with negative expression. Microvessel density (MVD) was positive corresponded with the grade, lymph
node metastasis and clinical stage (all P<0.05). The overall mean survival time of the patients with MVD≥22’s group
was shorter than that of patients with MVD<22’s group. Pathological-tumor-node-metastasis (pTNM) stage, positive
expression of CD133 and VM, postoperative therapy and MVD were independent prognostic factors of NSCLC
(P<0.05). Immunohistochemistry revealed an important intratumoral heterogeneity in all four CD133 expression
profiles.
Conclusions: VM, MVD and expression of CD133 are related to differentiation, lymph node metastasis, clinical
stage, and prognosis. It is suggested that CD133, VM and MVD should be considered as a potential marker for the
prognosis.Background
Lung cancer is among the most common form of cancer
of the respiratory system with an estimated incidence of
approximately 220,000 cases in the USA [1], and is the
leading cause of cancer-related mortality worldwide, with
nearly 1.4 million deaths each year [2], and non-small cell
lung cancer (NSCLC) accounts for nearly 85% of all cases
of lung cancer [1]. Worldwide, NSCLC is the most com-
mon form of cancer with overall 5-year survival rate of
less than 20.0% as most patients are diagnosed late and
are unsuitable for curative surgery. A major problem in
finding treatments is the frequent resistance to drugs
which emerges. This is linked to the development and
maintenance of small population of tumor cells, termed* Correspondence: tys101041@126.com
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reproduction in any medium, provided the orcancer stem cells (CSCs) or tumor-initiating cells (TIC).
These cells have been implicated in self-renewal, progres-
sion, and therapy-resistance in multiple solid cancers and
high tumorigenicity [3-13]. A commonly CSCs marker
is CD133, also known as prominin-1, a 120 kDa five
transmembrane domain cell surface glycoprotein, is ori-
ginally described as a surface antigen specific for human
hematopoietic stem and progenitor cells [14,15]. CD133 is
overexpressed in various solid tumors, including brain
[16], endometrial cancer [17], kidney [18], lung [19], liver
[20], gastric [21,22], colon [23], pancreas [24], breast [25],
skin [26] and prostate [27].
About tumor blood supply, the traditionally much atten-
tion has been focused on the role of angiogenesis [28].
Recently, Maniotis [29] and his coworkers had described
an angiogenesis-independent pathway called “vasculogenic
mimicry (VM)”, a new phenomenon in which highly. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and form vascular channel-like structures to convey blood
without the participation of endothelial cells. VM consists
of three formations: the plasticity of malignant tumor
cells, remodeling of the extracellular matrix (ECM), and
the connection of the VM channels to the host microcir-
culation system [30-33]. Later, in many aggressive tumors,
including breast carcinoma [34], glioma [35], hepatocellu-
lar carcinoma [36], clear cell renal cell carcinoma [37],
laryngeal squamous cell carcinoma [38], ovarian carci-
noma [39], gastric adenocarcinoma [40] and prostate car-
cinoma [41], have been described. VM is associated with
poor prognosis in tumor patients. The relationship
between CD133 and VM in NSCLC has not yet been
explored. In this study, we performed an immunohisto-
chemical investigation to explore the role of the CD133




Paraffin embedded sections of 305 NSCLCs and 30 distal
normal lung tissues were obtained from the Department
of Pathology, the First Hospital Affiliated to Bengbu
Medical College between 2003 and 2006 (Patients who
had received preoperative chemotherapy or radiotherapy
were excluded). This study was approved by the ethical
committee of the First Hospital Affiliated to Bengbu
Medical College before its start. The age of the patients
ranged from 26–82 years, the median age was 59.8 years.
Two hundred thirty-three were males and seventy-two
were females. Among the 305 cases, 248 were to post-
operative therapy (routine chemotherapy or radiothe-
rapy). Thirty-four were at grade I, two hundred three at
grade II, sixty-eight were at grade III, according to the
grading system of the World Health Organization
(WHO). Two hundred ten were squamous cell carci-
noma and ninety-five were adenocarcinoma. Two hun-
dred twenty-four were central type and eighty-one were
peripheral type. From lymph node metastasis, consisted
of one hundred twenty specimens of no metastasis and
one hundred eighty-five of yes metastasis. Fifty were
stage I, ninety were stage II, ninety-four were stage III
and seventy-one were stage IV, according to clinical sta-
ging of pTNM, respectively.
Immunohistochemistry
All samples were fixed 10% buffered formalin and em-
bedded in paraffin. 4 μm thick tissue sections were cut.
All sections were deparaffinnized and dehydrated with
graded alcohol. The sections were then washed 10 min
in phosphate-buffered saline (PBS) (pH 7.2). The en-
dogenous peroxidase activity was quenched by incuba-
tion in methanol containing 3% H2O2 for 10 min atroom temperature, then heated for 30 min at 95°C to
repair antigens and finally rinsed in PBS. After several
washes in PBS, the sections were blocked with goat
serum for 20 min at room temperature, and then incu-
bated with mouse monoclonal CD133 (Santa Cruz) and
CD34 (LabVision) primary antibodies overnight at 4°C in
a humidified chamber. Replacing the primary antibodies
by PBS, negative control staining was using performed,
the slides were treated with polymer enhancer (Reagent A)
for 20 min at room temperature. After a complete wash in
PBS, the slides were treated with goat anti-mouse anti-
body (Reagent B) for 30 min at room temperature. After a
complete wash in PBS, the slides were develop in freshly
prepared diaminobenzedine solution (DAB,) for 8 min,
and then counterstained with hematoxylin, dehydrated,
airdried, and mounted.
Evaluation of score
Slides were reviewed independently by two observers to
evaluate the staining pattern of the protein separately
under the light microscopy. In scoring expression of
CD133 and CD34 protein, both the extent and intensity
of immunopositivity were considered. The intensity of
positivity was scored as follows: 0, negative; 1, weak;
2, moderate; 3, strong. The extent of positivity was
scored according to the percentage of cells showing
positive staining: <10% is 1; 11%-50% is 2; 51%-75% is 3;
>75% is 4. The final score was determined by multiply-
ing the intensity of positivity and the extent of positivity
scores, yielding a range from 0 to 12. The expression for
CD133 and CD34 was considered positive when the
scores were >1.
The staining for CD133 was mainly confined to the
cytoplasm and membrane. The staining for CD34 was
mainly confined to the cytoplasm and membrane and
presented as brown granular materials. Microvessel
density (MVD) was determined by the mean number
of small CD34-positive vessels counted. A modified
Weidner’s method was used to calculate the MVD of
NSCLC by anti-CD34 immunostaining [42]. All samples
were submitted for PAS-CD34 dual staining to char-
acterize endothelial cells glycosylated basement mem-
branes of vessels as well as vessel-like (VM) channels
[43]. Moreover, no necrosis or hemorrhage in tumor
tissue near the VM channels was noted. The technique
was adopted from Yue et al. with some modifications
[44]. The observers selected ten high power fields and
counted individual microvessels.
Statistical analysis
Fisher’s exact test, Pearson Chi-square test for trends in
proportions, Spearman’s correlation coefficient test, and
Kaplan-Meier’s method with log rank test or Cox Re-
gression method for univariate or multivariate overall
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among the positive staining of CD133 or VM or MVD
and clinicopathological indices by SPSS 17.0 software for
windows (Chicago, IL). A value of P<0.05 was recog-
nized as statistically significant.Figure 2 Representative results of CD133 protein in non-small
cell lung cancer and control group. NSCLC cells did not express a
detectable level of CD133.Results
The association between expression of CD133, VM and
MVD and clinicopathological factors
CD133 protein was expressed positively in 48.9% (149/
305) of NSCLC and 26.7% (8/30) of distal normal lung
tissue. The staining for CD133 was confined to the
membrane and cytoplasm. There was a significant differ-
ence between the NSCLC group and the distal normal
lung tissue (P<0.05) (Figures 1, 2, and 3). There was a
significant difference between expression of CD133 and
histological grade, pTNM stage and lymph node metas-
tasis (P<0.001). None of the distal normal lung tissues
contained VM (Figure 4). Small vessel-like structures in
the tumor that were PAS-positive but CD34-negative
were to be VM channels. The cells external to the lumen
of the VM channels were positive for tumor cells, which
indicated the channels were formed by NSCLC cells
(Figure 5, 6, and 7). The presence as well as pattern
(linear, tubular, and network) of VM channels were
recorded in each case. VM was identified in NSCLC
tissue from 109 (35.7%) of 305 specimens of NSCLC.
There was a significant difference between the NSCLC
group and the distal normal lung group (P<0.05)
(Table 1). And the positive staining of VM and MVD
score were found to be closely linked to pTNM stages,
grade of tumors, lymph node metastasis in NSCLC
(P<0.05). However, the positive expression of CD133,
VM and MVD score were no significant association withFigure 1 Representative results of CD133 protein in non-small
cell lung cancer and control group. Control bronchiolar epithelial
cells expressed CD133 in the membrane and cytoplasm.gender, age, gross type, histological type and diameter of
tumors (P>0.05) (Table 1).Prognosis and multivariate analysis
Follow-up data showed that a significantly decreasing
trend in the overall mean survival time between the car-
cinomas with the expression of CD133 (19.0 months)
and those without (58.1 months)(Log rank=247.8, P <
0.001). The survival rate of the VM group was signifi-
cantly less than the non-VM group (P<0.001); the sur-
vival rate of the MVD<22 group was significantly more
than the MVD≥22 group (because the mean score of
MVD was 22.0±11.2) (Figures 8, 9 and 10. CD133, VM,
MVD, postoperative therapy and pTNM stages were in-
dependent prognostic factors by multivariate analysis
(P<0.05)) (Table 2).Figure 3 Representative results of CD133 protein in non-small
cell lung cancer and control group. CD133 predominantly
localized in the membrane and cytoplasm in moderately differentiated
squamous cell carcinoma (grade 2) (CD133×400)(black arrow is VM).
Figure 4 Representative results of VM in non-small cell lung
cancer and control group. No VM’s phenomenon in the control
group.
Figure 6 Representative results of VM in non-small cell lung
cancer and control group. Endothelial cells are detected with anti-
CD34 immunhistochemistry staning (dark brown) and vascular
basement membrane with PAS staining (purple magenta) (red
arrow: vessel stained positively with PAS but negatively with CD34;
black arrow: vessel stained positively with CD34).
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In positive expression of CD133 group, the mean score
of MVD was 29.4±9.8; in negative expression of CD133
group, the mean score of MVD was 15.0±7.2. There
was a positive correlation between CD133 and MVD
(r=0.685, P<0.001), and the same correlation between
VM and MVD (r=0.777, P<0.001). The positive corre-
lation between CD133 and VM was found (r=0.585,
P<0.001).
Discussion
Cancer stem cells, also known as tumor initiating cells,
are defined as a subset of tumor cells with the capacity
to self-renewal and give rise to the differentiated cells
that comprise the bulk of the tumor [3,5,6,9,13,45].
CD133 is commonly regarded as a marker of CSCs orFigure 5 Representative results of VM in non-small cell lung
cancer and control group. H&E staining in moderately
differentiated squamous cell carcinoma, red arrow is VM (Figure 3,
Figure 5 and Figure 6 are serial sections)(grade 2).TIC in many tumors [9,16-27]. Recently, CD133 has
been identified in more or equal to 50% of NSCLC,
colon, gastric and ovarian [9,19,22,46]. Lung cancer
CD133+ cells were able to grow indefinitely as tumor
spheres; upon differentiation, lung cancer CD133+ cells
acquired the specific lineage markers, while loosed the
tumorigenic potential together with CD133 expression
[47]. Furthermore, CD133+ cancer cells were more effi-
cient at forming clones and proliferated more extensively
than the CD133- population [46]. Lung cancer stem cells
are resistant to chemotherapeutic drugs, in line with the
poor therapeutic effect of conventional chemotherapy
on lung cancer patients [47]. Therefore, anti-CD133
gene-drug conjugates may warrant further evaluation asFigure 7 Representative results of VM in non-small cell lung
cancer and control group. VM in moderately differentiated
squamous cell carcinoma (red arrow is vessel, black arrow is VM)
(grade 2) (CD34+PAS×400).






valueNegative Positive Negative Positive (mean) F
Tissue <0.05 <0.001
Normal 22 8 0 30
NSCLC 156 149 196 109
Gender >0.05 >0.05 0.154 >0.05
Male 117 116 150 83 22.2±11.3
Female 39 33 46 26 21.6±10.9
Ages >0.05 >0.05 0.476 >0.05
<60 77 64 93 48 21.5±11.8
≥60 79 85 103 61 22.4±10.7
Gross type >0.05 >0.05 0.004 >0.05
Central 114 110 141 83 22.0±11.6
Peripheral 42 39 55 26 21.9±10.1
Histological type >0.05 >0.05 3.550 >0.05
Squamous carcinoma 111 99 141 69 21.2±11.3
Adenocarcinoma 45 50 55 40 23.8±10.7
Diameter of tumor >0.05 >0.05 0.133 >0.05
<3.0cm 13 17 20 10 21.3±11.1
≥3.0cm 143 132 176 99 22.1±11.2
Differentiation <0.001 <0.001 31.231 <0.001
Well 30 4 32 2 13.6±7.1
Moderate 104 99 142 61 20.9±9.7
Poor 22 46 22 46 29.6±12.9
Lymph node metastasis <0.001 <0.001 67.650 <0.001
Yes 71 114 93 92 25.9±10.2
No 85 35 103 17 16.1±10.0
pTNM stage <0.001 <0.001 200.694 <0.001
Iand II 111 29 129 11 14.3±6.7
III and IV 45 120 67 98 28.5±10.1
VM <0.001 471.458 <0.001
Negative 143 53 15.5±5.9
Positive 13 96 33.7±8.7
CD133 <0.001 216.747 <0.001
Negative 143 13 15.0±7.2
Positive 53 96 29.4±9.8
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cancer cells in lung cancer. To our data, there are no
reports about the prognostic significance and correlation
between CD133 expression and VM in NSCLC. Using
immunohistochemistry, we detect the expression of
CD133 in 149 (48.9%) and it is closely related to the
worst prognosis of NSCLC. Further research shows that
the expression of CD133 may be involved in grade of
NSCLC, lymphoid node metastasis and pTNM stages.
And the positive expression of CD133 indicates a shortersurvival time. Our study is consistent with parts of pre-
vious studies in lung carcinoma [48-50]. Another result
is that not only normal lung tissue (bronchiolar epithe-
lial cells) but also cancer cell expresses CD133. Although
CD133, which is the most accredited, is useful stem
cell markers, it is known to be expressed also in non-
stem cell populations and play an important role in
tumorigenesis [51]. It has been shown that CD133 is an
apical molecule in many normal human tissues and its
expression is not restricted to stem cells in pancreatic
Figure 8 Kaplan-Meier survival analysis by CD133, VM and MVD status (A is CD133; B is VM; C is MVD). (n=305). The y-axis represents
the percentage of patients; the x-axis, their survival in months. the green line represents CD133+ patients with a trend of worse survival than the
blue line representing CD133- non-small cell lung cancer patients (P<0.001). Mean survival times were 19.0 months for the CD133+ group and
58.1 months for the CD133- group.
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prognostic factor of some cancers, such as colon car-
cinoma, non-small cell lung cancer, hepatocellular car-
cinoma and cholangiocarcinoma [48-51,53-55]. Our
result is similar to the previous studies (including lung
and other tissues) [22,49,52,56]. As the population of
CD133+ cells in NSCLC may represent a relatively large
portion of cells (up to 48.9%) and only a part of CD133+Figure 9 Kaplan-Meier survival analysis by CD133, VM and MVD statu
the percentage of patients; the x-axis, their survival in months. The green li
than the blue line representing VM negative NSCLC patients (P<0.001). Me
51.4 months for the VM negative group.cells possesses the abilities of stem cells [47]. These can-
cer stem cells after routine chemo- and radio-therapy
may lead to tumor recurrence and metastasis through
the self-renewal, the multiple differentiating potential
and the proliferating aptitude in line with cancer stem
cell hypothesis [57].
Some highly aggressive human tumor cells mimic endo-
thelial cells and form vascular channel-like structures tos (A is CD133; B is VM; C is MVD). (n=305). The y-axis represents
ne represents VM positive patients with a trend of worse survival
an survival times were 16.9 months for the VM positive group and
Figure 10 Kaplan-Meier survival analysis by CD133, VM and MVD status (A is CD133; B is VM; C is MVD). (n=305). The y-axis represents
the percentage of patients; the x-axis, their survival in months. The green line represents MVD≥22 group(because the mean score of MVD is 22.0)
with a trend of worse survival than the blue line representing MVD<22 group NSCLC patients (P<0.001). Mean survival times were 19.8 months
for MVD≥22 group and 53.2 months for MVD<22 group.
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endothelial cells. In other words, the term VM is appro-
priate to describe the formation of these vascular channels
by tumor cells. In the H&E staining, we observe that VM
channels are composed of a basement membrane with
positive PAS staining and CD34- in the absence of endo-
thelial cells. Based on PAS and CD34 staining, some mor-
phologic patterns of VM including straight lines, arcs,
loops, networks and patterns have been described [58]. In
our study, VM is observed in 35.7% (109/305) of NSCLC
patients. And we find that VM is associated with grade of
tumor, lymph node metastasis and pTNM stages, which
are in agreement with previous reports [59,60]; further re-
search, we find that the VM-positive-group correlates with
the lower survival time, suggests that the existence of VM
increases the likelihood of hematogenous metastases and
is in inverse proportion to prognosis [34].
Microvessel density (MVD) is the standard method of
measuring tumor angiogenesis and is closely related with
tumor growth and postoperative prognosis. So the patients
with high scores of MVD indicate early metastasis andTable 2 Multivariate survival analysis of 305 patients
with NSCLC
Covariate B SE Sig Exp(B) 95%CI
pTNM 0.425 0.196 0.030 1.530 1.042-2.246
VM 0.649 0.226 0.004 1.914 1.229-2.982
CD133 1.632 0.181 0.000 5.116 3.587-7.298
MVD 0.515 0.226 0.023 1.674 1.075-2.606
Therapy 0.325 0.162 0.045 0.723 0.526-0.992short survival [61,62]. Our data is consistent with these
results. CD133 is not expressed in all tumors, and
expressed only a small fraction of the tumor cells in
CD133-positive tumors. The niche where CSCs reside
may regulate CSCs self-renewal. Vascular niche may regu-
late CSCs fate. Alternatively, perhaps CD133 is a marker
that does not initiate but rather enhances tumor growth,
for example, by means of better tumor vascularization
[51]. Our research also shows that CD133, VM and MVD
are positively correlated with each other in CD133-
positive population, suggesting that CSCs may be related
to angiogenesis and vasculogenic mimicry. CSCs have self-
renewal properties, multiple differentiating potential and
proliferating aptitude. Tumors require a blood and nu-
trient supply for growth and metastasis. When the dia-
meter of tumor is more than 1 mm3 in volume, tumor
can stimulate angiogenesis in order to get adequate blood,
the CD133 positive cells may contribute to the formation
of capillaries [62]. But when the blood supplied by neovas-
cularization cannot meet the needs of tumor growth, some
CSCs can mimic endothelial cells and form vascular
channel-like structures, which is VM [63]. The microvessel
and VM sustain CSCs self-renewal, multiple differentia-
ting potential and proliferating aptitude. The combined
detection of CD133, VM and MVD, to some extent, can
reflect the biological behavior of NSCLC cells, thus giving
the choice of molecular targeting therapy.
Conclusions
It is suggested that CD133 may play an important role
in the evolution of NSCLC. And CD133, VM and MVD
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nosis in patients with NSCLC.
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